Dora Ferrari

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Joachim von Pawel, Edward G. Garmey et al. · Journal of Clinical Oncology · 2011 · 379 citations · Full text

Medicine, Oncology, Pharmacology +15

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Tiziana Pressiani, C. Boni, Lorenza Rimassa et al. · Annals of Oncology · 2012 · 152 citations · Full text

Medicine, Oncology, Hepatic Pharmacokinetics +12

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

Jonathan W. Goldman, Isett Laux, Ronald E. Savage et al. · Cancer · 2012 · 77 citations · Full text

Medicine, Oncology, Pharmacology +15

Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome

Marjorie J. Lindhurst, Miranda R. Yourick, Yi Yu et al. · Scientific Reports · 2015 · 66 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +14

Quantifying survival in patients with Proteus syndrome

Julie C. Sapp, Lian Hu, Jean J. Zhao et al. · Genetics in Medicine · 2017 · 43 citations · Full text

Public Health, Internal Medicine, Survival Analysis +6